{"product_id":"arcusbio-marketing-mix","title":"Arcus Biosciences Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eArcus Biosciences pairs niche oncology therapeutics with targeted pricing and specialty-channel distribution to reach research-focused clinicians and biopharma partners; their promotional mix emphasizes scientific communications and key-opinion leader engagement to build credibility.\u003c\/p\u003e\n\u003cp\u003eGo beyond the preview—purchase the full 4Ps Marketing Mix Analysis for an editable, presentation-ready report that breaks down product positioning, pricing architecture, channel strategy, and promotional tactics with real data and actionable recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDomvanalimab Anti-TIGIT Antibody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDomvanalimab is an Fc-silent monoclonal antibody that blocks TIGIT on T and NK cells to boost anti-tumor immunity while avoiding Fc-mediated immune cell depletion.\u003c\/p\u003e\n\u003cp\u003eArcus positions domvanalimab as a potential best-in-class TIGIT asset by end-2025, targeting lung and GI cancers with ongoing Phase 2\/3 combinations showing objective response rates in early cohorts of 20–40% versus historical 10–25% for PD-(L)1 alone.\u003c\/p\u003e\n\u003cp\u003eIts Fc-silent design aims to lower immune-related adverse events; in pooled trials through 2024 Grade 3–4 irAE rates remained under 10%, supporting tolerability for multi-agent regimens and potential commercial premium.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCasdatifan HIF-2a Inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCasdatifan, Arcus Biosciences' oral HIF-2a inhibitor, targets clear cell renal cell carcinoma and drove Arcus into solid tumors; as of late 2025 phase 2 data showed a 42% objective response rate (ORR) and median progression-free survival of 8.4 months versus ~30% ORR for early entrants, suggesting superior potency and PK.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eZimberelimab Anti-PD-1 Monoclonal Antibody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eZimberelimab (anti-PD-1) is Arcus’s in-house backbone, letting the company pair it with domvanalimab and quemliclustat across multiple trials without licensing external PD-1s, lowering COGS and partner fees.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 Zimberelimab is active in X+ Phase 1\/2 programs, supporting efficacy boosts seen in early data (ORR lifts ~10–20%), and cutting projected regimen spend by an estimated 15–25% versus outsourced PD-1s.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuemliclustat CD73 Inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpquemliclustat is a potent small-molecule cd73 inhibitor that blocks tumor production of immunosuppressive adenosine aiming to restore anti-tumor immunity in adenosine-rich pancreatic and lung cancers.\u003e\n\u003cpby end-2025 arcus advanced quemliclustat into late-stage trials for pancreatic and non-small cell lung cancer phase enrollment targets patients across both programs with topline readouts expected\u003e\n\u003cpthe product targets patients who progressed on chemo or immunotherapy modeling shows a peak-addressable us market of and potential peak sales range depending combination approvals pricing.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMechanism: CD73 inhibition reduces adenosine, restores T-cell activity\u003c\/li\u003e\n\u003cli\u003eDevelopment status: Late-stage (Phase 3) by end-2025\u003c\/li\u003e\n\u003cli\u003eIndications: Pancreatic cancer, non-small cell lung cancer\u003c\/li\u003e\n\u003cli\u003eEnrollment target: ~600 patients; readouts 2026–2027\u003c\/li\u003e\n\u003cli\u003eMarket: ~40,000 US patients\/year; peak sales est. $500M–$1.2B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pby\u003e\u003c\/pquemliclustat\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEtrumaadenant Adenosine Receptor Antagonist\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpetrumaadenant a dual a2a adenosine receptor antagonist aims to block adenosine-driven suppression of t cells and myeloid improving anti-tumor immunity in selected cancers.\u003e\n\u003cparcus focuses etrumaadenant on patients where adenosine signaling drives progression notably subsets of colorectal cancer trials target biomarker-defined cohorts to increase response rates.\u003e\n\u003cpby late etrumaadenant remains central to arcus adenosine strategy alongside antibody and small-molecule programs r spend on the portfolio was about in\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDual A2a\/A2b blockade: restores T-cell\/myeloid function\u003c\/li\u003e\n\u003cli\u003eTarget: adenosine-driven colorectal cancer subtypes\u003c\/li\u003e\n\u003cli\u003eLate-2025 role: core to multi-angle adenosine approach\u003c\/li\u003e\n\u003cli\u003e2024 adenosine portfolio R\u0026amp;D spend: ~$85M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pby\u003e\u003c\/parcus\u003e\u003c\/petrumaadenant\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcus: Five late‑stage IO candidates targeting 40k US pts\/yr, $500M–$1.2B peak sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcus’s product portfolio centers on domvanalimab (Fc-silent anti-TIGIT), casdatifan (oral HIF-2a), zimberelimab (in-house anti-PD-1), quemliclustat (CD73 inhibitor) and etrumaadenant (A2a\/A2b antagonist), all advanced into Phase 2\/3 by late 2025 targeting lung, GI, RCC, pancreatic and biomarker-defined colorectal cohorts with combined peak US addressable ~40,000 pts\/yr and peak sales $500M–$1.2B.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDomvanalimab\u003c\/td\u003e\n\u003ctd\u003eLung\/GI\u003c\/td\u003e\n\u003ctd\u003ePhase 2\/3\u003c\/td\u003e\n\u003ctd\u003eORR 20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCasdatifan\u003c\/td\u003e\n\u003ctd\u003eccRCC\u003c\/td\u003e\n\u003ctd\u003ePhase 2 (late)\u003c\/td\u003e\n\u003ctd\u003eORR 42%; PFS 8.4m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZimberelimab\u003c\/td\u003e\n\u003ctd\u003eBackbone PD-1\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2\u003c\/td\u003e\n\u003ctd\u003eCost cut 15–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuemliclustat\u003c\/td\u003e\n\u003ctd\u003ePancreatic\/NSCLC\u003c\/td\u003e\n\u003ctd\u003ePhase 3\u003c\/td\u003e\n\u003ctd\u003e600 pt programs; readouts 2026–27\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEtrumaadenant\u003c\/td\u003e\n\u003ctd\u003eColorectal subsets\u003c\/td\u003e\n\u003ctd\u003eLate-stage\u003c\/td\u003e\n\u003ctd\u003e2024 adenosine R\u0026amp;D $85M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Arcus Biosciences’ Product, Price, Place, and Promotion strategies, using real practices and competitive context to ground insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Arcus Biosciences’ 4P marketing insights into a concise, at-a-glance view to quickly relieve decision-making pain points for leadership and cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGilead Sciences Strategic Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary distribution and commercialization channel for Arcus products is Gilead Sciences under a ten-year collaboration signed in 2020, granting Arcus access to Gilead’s $27.8 billion 2024 global revenue-scale commercial infrastructure and sales force in 35+ countries. By end-2025 the deal enables rapid international roll-out of newly approved therapies, potentially reaching markets representing \u0026gt;70% of global pharma sales. This partnership reduces Arcus’s go-to-market capex and accelerates peak revenue timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Clinical Trial Site Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArcus Biosciences operates a global clinical trial site network across 120+ sites in North America, Europe, and Asia-Pacific, placing experimental therapies in major medical hubs for initial patient delivery and data capture.\u003c\/p\u003e\n\u003cp\u003eThese sites enrolled over 3,200 patients in 2024 trials, generating pivotal safety and efficacy datasets used in regulatory filings with FDA, EMA, and PMDA.\u003c\/p\u003e\n\u003cp\u003eGeographic diversity supports demographic requirements for global market authorization, covering 25+ countries and reducing regional regulatory risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy and Hospital Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpupon commercialization arcus biosciences will distribute through specialized oncology pharmacy networks and high-acuity hospital systems targeting regional cancer centers in the us to handle biologics precision medicines requiring cold-chain logistics clinician administration. by late finalized frameworks cutting average shipment time hours securing third-party contracts covering of zip codes with centers. these channels support higher asps selling prices for per course enabling physician-led infusion monitoring.\u003e\n\u003c\/pupon\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutional Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eArcus places its oncology candidates at leading academic medical centers to drive physician-led research and boost brand familiarity among top-tier oncologists; in 2024 over 60% of Arcus trials listed principal investigators at NCI-designated centers.\u003c\/p\u003e\n\u003cp\u003eThese centers act as hubs that shape standards of care—studies show academic-originated trials account for ~45% of practice-changing oncology approvals from 2015–2023—so early placement speeds adoption at commercialization.\u003c\/p\u003e\n\u003cp\u003eReal-world use at these sites is crucial to prove clinical utility for complex combination therapies; payer dossiers and formulary approvals cite academic real-world evidence in ~70% of oncology reimbursement decisions in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e60%+ Arcus trials led from NCI centers (2024)\u003c\/li\u003e\n\u003cli\u003e45% of practice-changing approvals from academic trials (2015–2023)\u003c\/li\u003e\n\u003cli\u003e70% of oncology reimbursement decisions cite academic real-world evidence (2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized Third-Party Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eArcus partners with centralized third-party logistics (3PL) providers to handle storage and distribution of clinical and future commercial supplies, leveraging specialized cold-chain and GMP-compliant infrastructure for small molecule and biologic oversight.\u003c\/p\u003e\n\u003cp\u003eCentralization cuts overhead—3PL consolidation reduced comparable biotech logistics spend by ~18% in 2024—and preserves product integrity across cold chain; Arcus targets similar savings through 2025 while meeting regulatory traceability standards.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses GMP cold-chain 3PLs for biologics and small molecules\u003c\/li\u003e\n\u003cli\u003eAims ~18% logistics cost reduction vs decentralized model (peer 2024 benchmark)\u003c\/li\u003e\n\u003cli\u003eMaintains end-to-end traceability and regulatory compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArcus + Gilead: 70% market reach, 150+ centers, 24–48h delivery, ~18% logistics savings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eArcus distributes via Gilead’s commercial network (10-year deal from 2020), clinical sites (120+ global sites; 3,200+ trial patients in 2024), 150+ regional cancer centers for commercial infusions, and GMP cold-chain 3PLs targeting ~18% logistics savings; partnerships enable access to \u0026gt;70% global pharma markets and 24–48h delivery to centers by late 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGilead deal\u003c\/td\u003e\n\u003ctd\u003e10-year from 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal sites\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial patients (2024)\u003c\/td\u003e\n\u003ctd\u003e3,200+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoverage of pharma sales\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegional centers\u003c\/td\u003e\n\u003ctd\u003e150+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDelivery time\u003c\/td\u003e\n\u003ctd\u003e24–48 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics savings target\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eArcus Biosciences 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Arcus Biosciences 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750263271801,"sku":"arcusbio-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/arcusbio-marketing-mix.png?v=1772223727","url":"https:\/\/matrixbcg.com\/products\/arcusbio-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}